1114P - All.Can initiative – improving efficiency in cancer care

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Cancer in Adolescents
Bioethics, Legal, and Economic Issues
Presenter Matti Aapro
Citation Annals of Oncology (2017) 28 (suppl_5): v395-v402. 10.1093/annonc/mdx375
Authors M.S. Aapro1, S. Chrostowski2, F. Florindi3, B. Gandouet4, S. Hanna5, R. Hazarika6, R. Hess7, F. de Lorenzo8, V. Muthu9, K. Oliver10, A. Roediger11, T. Rosvall-Puplett12, B. Ryll13, G. Spurrier14, K. Steinmann15, T. Szucs16, S. Wait17, L. Wierinck18, W. Yared19
  • 1Cancer Center, Clinique de Genolier, 1272 - Genolier/CH
  • 2Polish Cancer Patient coalition, Polish Cancer Patient Coalition, Warsaw/PL
  • 3European Cancer Patient Coalition (ecpc), European Cancer Patient Coalition (ECPC), 1000 - Brussels/BE
  • 4Oncopole-sciences Du Vivant Et Santé Publique, Oncopole-Sciences du Vivant et Santé Publique, Toulouse/FR
  • 5Save Your Skin Foundation, Save Your Skin Foundation, Laval/CA
  • 6The International Consortium For Health Outcomes Measurement, The International Consortium for Health Outcomes Measurement, London/GB
  • 7Gvg-committee On Health Goals, GVG-Committee on Health Goals, Cologne/DE
  • 8European Cancer Patients coalition, European Cancer Patients Coalition, Brussels/BE
  • 9Marivek Health Consulting, Marivek Health Consulting, London/GB
  • 10The International Brain Tumour Alliance, The International Brain Tumour Alliance, London/GB
  • 11Oncology, MSD, Luzer/CH
  • 12Oncology, Bristol Myers-Squibb, Braine l'Alleud/BE
  • 13Melanoma Patient Network Europe, Melanoma Patient Network Europe, Uppsala/SE
  • 14Melanoma Patient Network Europe, Melanoma Patient Network Europe, Clermont-Ferrand/FR
  • 15Corporate Affairs, Amgen, Zug/CH
  • 16University Of Basel, University of Basel, Basel/CH
  • 17The Health Policy Partnership, The Health Policy Partnership, WC2N4JS - London/GB
  • 18European Parliament, European Parliament, Brussels/BE
  • 19Association Of European Cancer Leagues, Association of European Cancer Leagues, Brussels/BE

Abstract

Background

In industrialised countries, about 20% of healthcare spending is currently wasted on ineffective interventions. With growing cancer prevalence and the increasing complexity of care, efficiency must improve – defined as delivering better outcomes to patients for the resources available.

Methods

The All.Can initiative was set up as a multi-stakeholder platform to engage policymakers on the need to remove obsolescence and focus resources on what matters most to patients across the cancer care continuum. Members of the group include patient organisations, policymakers, healthcare professionals, research and industry representatives from across Europe and Canada. All.Can has a continued programme of research and policy engagement to achieve its aims.

Results

The group issued the following policy recommendations: focus care on what matters most to patients; invest in data to evaluate and monitor whether care is delivering optimal outcomes; instil accountability mechanisms across the cancer care pathway, creating a cycle of continuous improvement; and build political to drive meaningful change to systematise good practice. As a starting point however, we need clear definitions of waste and inefficiency from the patient perspective. All.Can will conduct a comprehensive qualitative survey of cancer patients to create a patient-relevant conceptual framework for waste and inefficiency. The survey will also be extended to oncology specialists. Findings will help determine where greatest opportunities lie to improve efficiency in cancer care, and serve as a basis for concrete policy proposals that may make the greatest difference to cancer patients.

Conclusions

Improving efficiency across the entire cancer care pathway is a complex and pressing challenge that will require close collaboration between all stakeholders. The All.Can initiative is a promising way forward.

Clinical trial identification

Not applicable

Legal entity responsible for the study

The Health Policy Partnership Ltd

Funding

Bristol-Myers Squibb, Amgen and MSD

Disclosure

A. Roediger: Employment with MSD. T. Rosvall-Puplett: Employment with Bristol-Myers Squibb. K. Steinmann: Employment with Amgen. S. Wait: Received consultancy fees from Amgen, MSD and Bristol-Myers Squibb (the funders of All.Can) through organisation, the Health Policy Partnership, for providing secretariat to All.Can. All other authors have declared no conflicts of interest.